Newcastle Disease Virus at the Forefront of Cancer Immunotherapy
/in International Publications, Newcastle Disease VirusMitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
/in International Publications, IOZK VeröffentlichungenA Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)
/in Dendritic Cells, Gallbladder Cancer, International PublicationsOncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusModulated Electrohyperthermia: A New Hope for Cancer Patients
/in Hyperthermia, International PublicationsAdoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine
/in Breast Cancer, Dendritic Cells, International PublicationsHigh Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
/in Dendritic Cells, International Publications, Prostate CancerEmerging Immunotherapies in the Treatment of Brain Metastases
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease VirusTh17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer